Business Context and Reporting Period
Cocrystal Pharma, Inc. (COCP) filed a Form 8-K on December 15, 2023, reporting the termination of a material definitive agreement. The company is incorporated in Delaware and trades on The Nasdaq Capital Market.
Key Financial Metrics
This filing does not provide current revenue, profit, cash flow, margin, debt, or liquidity metrics. The document references a historical upfront payment of $4,000,000 received in January 2019 under the terminated agreement. The filing text does not provide a clear value for any other financial figures.
Material Changes
- Agreement Termination: Merck Sharp & Dohme LLC elected to terminate the Exclusive License and Research Collaboration Agreement dated January 2, 2019.
- Effective Date: The termination is effective March 14, 2024.
- Reason for Termination: Merck determined there were no existing conditions to continue the collaboration due to the inability to develop influenza A/B antiviral compounds to meet a specific aspect of Merck's program.
- Historical Context: The Company completed all research obligations in January 2021, after which Merck was solely responsible for further development and commercialization.
Outlook, Risks, and Contingencies
The termination eliminates the potential for future milestone payments and royalties on product sales derived from the collaboration. Pending patent applications on compounds covered by the Agreement remain in place. The filing does not provide specific forward-looking guidance or management commentary beyond the notification of the termination.
Investor Verification Checklist
- Verify the impact of the lost collaboration on the Company's future revenue pipeline and cash burn rate.
- Confirm the status of pending patent applications and whether Cocrystal retains any rights to the compounds post-termination.
- Review recent quarterly reports (10-Q/10-K) for updated liquidity and cash position data not included in this 8-K.
- Assess whether the termination triggers any change of control provisions or other contractual obligations in existing agreements.